Michael David Garrison, who serves as the Executive Vice President and President of Medical Essentials and BioPharm at Becton Dickinson & Co (NYSE: BDX), executed a significant transaction involving the company's equity on June 10, 2026. According to filings, Mr. Garrison sold a total of 1,100 shares of Becton Dickinson common stock. The transaction was valued at $166,628, with each share disposed of at a price of $151.48.
This sale was executed under the framework of a Rule 10b5-1 trading plan. Mr. Garrison originally adopted this pre-arranged trading plan on February 18, 2026. Following the completion of this transaction, Mr. Garrison's direct holdings in Becton Dickinson common stock stand at 14,272 shares. These direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by Mr. Garrison.
Market data indicates that Becton Dickinson stock currently trades at $147.35. This current price is below the $151.48 per share price at which Mr. Garrison executed his sale. Analysis from InvestingPro suggests that the company is undervalued relative to its Fair Value. This assessment places Becton Dickinson among the compelling opportunities on the platform's list of most undervalued stocks. Becton Dickinson, a healthcare equipment giant, has raised its dividend for 55 consecutive years. The company is covered in depth through a comprehensive Pro Research Report available to subscribers.
In other recent developments, Becton Dickinson reported its Q2 2026 earnings, exceeding analyst expectations. The company reported an adjusted earnings per share (EPS) of $2.90, surpassing the forecasted $2.78. The company’s revenue for the quarter was $4.7 billion, slightly above the anticipated $4.67 billion. Additionally, BD has introduced the Elyra Thulium Fiber Laser System, designed for urologic stone management and soft tissue procedures. This new system comes in two configurations, Elyra and Elyra Plus, to meet varying operational needs.
In financial developments, BD’s subsidiary, Becton Dickinson Euro Finance S.à r.l., completed an underwritten public offering of €600 million in notes due 2033, guaranteed by BD. Furthermore, BD has appointed Peter Menziuso as the executive vice president and president of its Interventional unit, effective June 1. Menziuso previously held a leadership role at Johnson & Johnson Vision. These recent developments highlight BD’s ongoing strategic and financial activities.
Market data shows BDX trading at $147.35, down $0.44 or 0.30% in closed trading. After hours trading shows BDX at $147.00, down $0.35 or 0.24%. The stock's performance is tracked across multiple timeframes, including 1 day, 1 week, 1 month, 6 months, 1 year, 5 years, and maximum periods.